Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGFBP-2 Vaccine in Recurrent Ovarian Cancer
NCT07495124Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
A Phase 2 trial of pUMVC3-IGFBP-2 in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by University of Washington. Started Sep 2026; status: recruiting.
02
Drugs
pUMVC3-IGFBP-2
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07495124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07495124.